{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:41:58Z","timestamp":1791009718289,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1038\/sj.bjc.6605740","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T20:02:25Z","timestamp":1277236945000},"page":"196-200","source":"Crossref","is-referenced-by-count":81,"title":["Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience"],"prefix":"10.1038","volume":"103","author":[{"given":"P","family":"Str\u00f6bel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Manegold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"key":"BF6605740_CR1","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1073\/pnas.0804543106","volume":"106","author":"K Al-Nedawi","year":"2009","unstructured":"Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J (2009) Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA 106: 3794\u20133799","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6605740_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1083\/jcb.200608093","volume":"177","author":"SG Ball","year":"2007","unstructured":"Ball SG, Shuttleworth CA, Kielty CM (2007) Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 177: 489\u2013500","journal-title":"J Cell Biol"},{"issue":"Suppl","key":"BF6605740_CR3","doi-asserted-by":"publisher","first-page":"No. 19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","volume":"26","author":"P Bedano","year":"2008","unstructured":"Bedano P, Perkins S, Burns M, Kessler KA, Nelson R, Schneider B, Risley L, Dropcho S, Loehrer Sr PJ (2008) A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 26 (Suppl): No. 19087","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","volume":"4","author":"G Bisagni","year":"2009","unstructured":"Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C (2009) Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 4: 773\u2013775","journal-title":"J Thorac Oncol"},{"key":"BF6605740_CR5","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","volume":"26","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810\u20131816","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884\u2013896","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR7","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","volume":"24","author":"C Chuah","year":"2006","unstructured":"Chuah C, Lim TH, Lim AS, Tien SL, Lim CH, Soong R, Lee F, Linn YC, Goh YT, Cheah FK, Loh AH (2006) Dasatinib induces a response in malignant thymoma. J Clin Oncol 24: e56\u2013e58","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329\u20131338","journal-title":"Lancet"},{"key":"BF6605740_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/annonc\/mdp111","volume":"20","author":"M Dror Michaelson","year":"2009","unstructured":"Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20: 913\u2013920","journal-title":"Ann Oncol"},{"key":"BF6605740_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247","journal-title":"Eur J Cancer"},{"key":"BF6605740_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ijrobp.2003.11.021","volume":"59","author":"TY Eng","year":"2004","unstructured":"Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas Jr CR (2004) Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 59: 654\u2013664","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF6605740_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/j.semtcvs.2004.11.003","volume":"17","author":"TL Evans","year":"2005","unstructured":"Evans TL, Lynch TJ (2005) Role of chemotherapy in the management of advanced thymic tumors. Semin Thorac Cardiovasc Surg 17: 41\u201350","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"BF6605740_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734\u2013745","journal-title":"Nat Rev Drug Discov"},{"key":"BF6605740_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1053\/j.seminoncol.2006.04.005","volume":"33","author":"S Faivre","year":"2006","unstructured":"Faivre S, Djelloul S, Raymond E (2006) New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33: 407\u2013420","journal-title":"Semin Oncol"},{"key":"BF6605740_CR15","first-page":"304","volume":"63","author":"CA French","year":"2003","unstructured":"French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63: 304\u2013307","journal-title":"Cancer Res"},{"key":"BF6605740_CR16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1097\/MPH.0b013e318159a535","volume":"29","author":"GP Kertesz","year":"2007","unstructured":"Kertesz GP, Hauser P, Varga P, Dabasi G, Schuler D, Garami M (2007) Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach. J Pediatr Hematol Oncol 29: 774\u2013775","journal-title":"J Pediatr Hematol Oncol"},{"key":"BF6605740_CR17","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.athoracsur.2008.11.022","volume":"87","author":"RJ Korst","year":"2009","unstructured":"Korst RJ, Kansler AL, Christos PJ, Mandal S (2009) Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 87: 1641\u20131647","journal-title":"Ann Thorac Surg"},{"key":"BF6605740_CR18","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","volume":"26","author":"MH Kulke","year":"2008","unstructured":"Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26: 3403\u20133410","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR19","doi-asserted-by":"publisher","first-page":"No. 7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","volume":"23, 16s","author":"A Kurup","year":"2005","unstructured":"Kurup A, Burns M, Dropcho S, Pao W, Loehrer Sr PJ (2005) Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 23, 16s: No. 7068","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3816\/CLC.2004.n.018","volume":"6","author":"A Kurup","year":"2004","unstructured":"Kurup A, Loehrer Sr PJ (2004) Thymoma and thymic carcinoma: therapeutic approaches. Clin Lung Cancer 6: 28\u201332","journal-title":"Clin Lung Cancer"},{"key":"BF6605740_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","volume":"26","author":"XF Li","year":"2009","unstructured":"Li XF, Chen Q, Huang WX, Ye YB (2009) Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 26: 157\u2013160","journal-title":"Med Oncol"},{"key":"BF6605740_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115\u2013124","journal-title":"N Engl J Med"},{"key":"BF6605740_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","volume":"7","author":"C Porta","year":"2007","unstructured":"Porta C, Paglino C, Imarisio I, Bonomi L (2007) Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7: 127\u2013134","journal-title":"Clin Exp Med"},{"key":"BF6605740_CR24","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1158\/1535-7163.MCT-03-0156","volume":"5","author":"O Potapova","year":"2006","unstructured":"Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB (2006) Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5: 1280\u20131289","journal-title":"Mol Cancer Ther"},{"key":"BF6605740_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1470-2045(09)70017-8","volume":"10","author":"P Rutkowski","year":"2009","unstructured":"Rutkowski P, Ruka W (2009) Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol 10: 157\u2013163","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"BF6605740_CR26","doi-asserted-by":"publisher","first-page":"No. 8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","volume":"26","author":"J Salter","year":"2008","unstructured":"Salter J, Lewis D, Yiannoutsos C, Loehrer Sr PJ, Risley L, Chiorean E (2008) Imatinib for the treatment of thymic carcinoma. J Clin Oncol 26 (Suppl): No. 8116","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR27","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1200\/JCO.2007.12.8637","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ (2007) Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25: 4793\u20134799","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","volume":"26","author":"MA Socinski","year":"2008","unstructured":"Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650\u2013656","journal-title":"J Clin Oncol"},{"key":"BF6605740_CR29","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Strobel","year":"2004","unstructured":"Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, Marx A (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350: 2625\u20132626","journal-title":"N Engl J Med"},{"key":"BF6605740_CR30","volume-title":"Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart","author":"WD Travis","year":"2004","unstructured":"Travis WD, Brambilla E, Muller-Hermelink HK, Harris CCE (2004) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart Vol. 7. World Health Organization Classification of Tumours Lyon: IARC Press"},{"key":"BF6605740_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","volume":"62","author":"M Tsuchida","year":"2008","unstructured":"Tsuchida M, Umezu H, Hashimoto T, Shinohara H, Koike T, Hosaka Y, Eimoto T, Hayashi JI (2008) Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 62: 321\u2013325","journal-title":"Lung Cancer"},{"key":"BF6605740_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1053\/j.semtcvs.2004.12.001","volume":"17","author":"CD Wright","year":"2005","unstructured":"Wright CD, Kessler KA (2005) Surgical treatment of thymic tumors. Semin Thorac Cardiovasc Surg 17: 20\u201326","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"BF6605740_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","volume":"62","author":"K Yoh","year":"2008","unstructured":"Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, Saijo N (2008) Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 62: 316\u2013320","journal-title":"Lung Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605740","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:45:40Z","timestamp":1684413940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["BF6605740"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605740","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]}}}